Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : The thread of life -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (476)	5/31/2003 1:00:29 AM
From: scaram(o)uche	Respond to of 1336

>> I can see why Rick uses Delphion << Too expensive for me. I use EPO, if I'm searching company name, and then double check at USPTO for anything "U.S." that might have escaped. If I'm searching for prior art, I start with USPTO and then back up with EPO. But the EPO site is really whacko. For some reason, old stuff sometimes floats to the top. And the search interface is weak, IMO. The U.S. search interface is great, but, for applications rather than issued patents, assignees are often not there (not required, for PCT applications??). Delphion is great. They catch everything, and present it to you in a great, easy-to-use format. I used it when it was a freebie. When they were devising their pricing, I tried to convince them that they could sell a crippled version, but searching all databases, to investors if they kept the price at a decent hurt. (I do have a Delphion account, with lots of customization, that I didn't want to share during that trial period. I should have thought and set up a second, as Donald Duck..... if I could get around cookies, without globally disarming them.)

To: tuck who wrote (476)	5/31/2003 11:40:31 AM
From: Mike McFarland	Read Replies (2) \| Respond to of 1336

I read here med.unc.edu that there are lentivirus proteins toxic to the cell lines, as well as the toxic VSV used to pseudotype. Sure enough here is part of what they do (from Baltimore patent). Of course, 98% of this is going over my head, but thanks for the patents! [0097] In the preferred embodiment a packaging cell line that does not stably express viral proteins is transfected with the viral construct, a second vector comprising the HIV-1 packaging vector with the env, nef, 5'LTR, 3'LTR and vpu sequences deleted, and a third vector encoding an envelope glycoprotein. Preferably the third vector encodes the VSVg envelope glycoprotein. Hell, I probably wont even get to my Rigel stuff which finally showed up in the mail yesterday. Thanks again Tuck! Oh, interesting tidbit: Garry Nolan (who was one of of the founders of Rigel) does this stuff. You can visit his lab here: stanford.edu